E. de Stanchina

The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1

This study identifies ASCL1 as a critical driver of neuroendocrine lineage transition in prostate cancer using an in vivo model and spatial transcriptomics.

Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity

This study shows that SMARCA4 mutations in ovarian cancer increase immunogenicity through interferon response and epigenetic changes, enhancing T cell and NK cell activity in the tumor microenvironment.

ERG activates a stem-like proliferation-differentiation program in prostate epithelial cells with mixed basal-luminal identity

The paper identifies a stem-like proliferative state in prostate epithelial cells driven by ERG activation, which transitions to luminal cells and is associated with specific chromatin states.

FET fusion oncoproteins disrupt physiologic DNA repair and create a targetable opportunity for ATR inhibitor therapy

This study shows FET fusion oncoproteins disrupt DNA repair by inhibiting ATM signaling, making ATR inhibitors a potential therapy for FET rearranged cancers.

Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy

This study identifies mechanisms of resistance to EZH2 inhibition in SMARCB1-deficient cancers and proposes combination therapies to overcome resistance.

EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance

This study shows that inhibiting EZH2 enhances pro-inflammatory SASP in pancreatic cancer, improving NK and T cell infiltration and tumor control in mouse models.

CD39 Identifies Tumor-Reactive CD8 T cells in Patients With Lung Cancer

This study identifies CD39 as a marker for tumor-reactive CD8 T cells in lung cancer, showing its association with clinical outcomes and response to immune checkpoint therapy.

A molecular switch between mammalian MLL complexes dictates response to Menin-MLL inhibition

The paper identifies a molecular switch between MLL1-Menin and MLL3/4-UTX complexes that determines response to Menin-MLL inhibitors in leukemia.

ERα-LBD, a novel isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance

The paper identifies ER-LBD, a novel estrogen receptor alpha isoform, which promotes breast cancer growth and resistance to endocrine therapy.

Regional and clonal T cell dynamics at single cell resolution in immune checkpoint blockade

This study uses scTCR/RNA-seq to analyze T cell dynamics in lung cancer patients before and after ICB, finding regional heterogeneity and clonal persistence associated with clinical responses.

Adaptive stimulation of macropinocytosis overcomes aspartate limitation in cancer cells under hypoxia

The paper identifies GOT2-catalyzed mitochondrial aspartate synthesis as essential for pancreatic tumor cell proliferation under hypoxia, but this dependency is bypassed by hypoxia-induced macropinocytosis.

Establishment of multiple novel patient-derived models of desmoplastic small round cell tumor enabling functional characterization of ERBB pathway signaling and pre-clinical evaluation of a novel targeted therapy approach

This study develops new DSRCT models and shows that targeting the ERBB pathway with EGFR inhibitors reduces tumor growth in preclinical models.

Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics

This study develops a CRISPR-Cas9 lentiviral platform for genome editing of patient-derived xenografts to analyze genetic dependencies and drug resistance mechanisms in vivo.

Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma

This paper shows that HDAC3 inhibitors reverse CREBBP mutation-driven epigenetic changes in lymphoma, inhibiting tumor growth and restoring immune surveillance.

Peptidomimetic blockade of MYB in acute myeloid leukemia

This study develops a peptidomimetic inhibitor, MYBMIM, that blocks MYB:CBP/P300 complex assembly in AML cells, leading to apoptosis and reduced tumor growth in mice.

Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors

This study identifies PGBD5 as a therapeutic target in pediatric solid tumors, showing that inhibiting DNA repair pathways with AZD6738 sensitizes these tumors to apoptosis.

Human PGBD5 DNA transposase promotes site-specific oncogenic mutations in rhabdoid tumors

This study identifies PGBD5 as an oncogenic DNA transposase in rhabdoid tumors, causing site-specific genomic rearrangements through PSS sequences and end-joining repair.